B+
Bull case
25%
Probability
Target price
$16.00
+32.7% vs current
BVS
BioventusANasdaq / Health Care Equipment & Services
Last Price
At close
2026-07-18
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$13.50
+11.9% vs current
B-
Bear case
25%
Probability
Target price
$9.00
-25.4% vs current
AI sentiment snapshot
Latest data as of 2026-07-15
Recent news sentiment (30D)
+30.0
Positive
Company
-
Unavailable
Macro
+30.0
Positive
Pulse
-
Unavailable
Sentiment proxy
+53.6
Score
AI commentary
Primary SEC evidence is constructive after Q1, and the deterministic prior is positive. However, coverage is low, news is sparse, social/options/short-interest data are unavailable, and valuation plus rebate normalization risks support a monitoring-style rather than high-conviction thesis.
RankAlpha Sentiment Codex - 2026-07-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-06eventQ1 results and raised full-year guidanceHigh impact
Q1 revenue increased 7% to $132.1 million, adjusted EBITDA rose 24% to $23.9 million, operating cash flow improved to $8.9 million, and the company raised non-GAAP EPS and cash-from-operations guidance while reaffirming revenue guidance. [#SEC-8K-2026-05-06]
2026-10-13catalystValuation leaves room for execution-driven multiple compressionHigh impact
A secondary valuation check in the packet places BVS at roughly 28.3x P/E versus a 26.6x industry average and estimates a fair P/E near 24.8x; weaker growth or cash conversion could pressure the multiple.
2027-07-15catalystSustained cash conversion could support reratingHigh impact
If broad-based growth and improved cash generation persist beyond Q1, profitability and balance-sheet progress could support a higher valuation multiple. [#SEC-8K-2026-05-06]
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-15 • Updated nightlySource: Internal modelMethodology